S. Kacerovsky-Strobl

Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18

M. Gnant, F. Fitzal, C. Singer, 2022, ESMO open.

San Antonio 2020 update—the top 3 surgical abstracts

S. Kacerovsky-Strobl, 2021, memo - Magazine of European Medical Oncology.

Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12.

G. Pond, M. Gnant, M. Clemons, 2022, European journal of cancer.

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.

R. Greil, M. Gnant, R. Jakesz, 2021, The New England journal of medicine.

Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer.

R. Greil, J. Bergh, F. Kainberger, 2022, NEJM evidence.

Third International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)

P. V. van Diest, M. Gnant, R. Mann, 2023, Virchows Archiv.

Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.

M. Gnant, C. Isaacs, A. DeMichele, 2022, Journal of Clinical Oncology.

Explaining risks and benefits of loco-regional treatments to patients

Michael Gnant, A. Beltran-Bless, S. Kacerovsky-Strobl, 2023, Breast.

Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

K. Gelmon, M. Gnant, C. Isaacs, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.